Global Antiemetics Drugs Market Size, Share, and COVID-19 Impact Analysis, Drug Type (Serotonin-Receptor Antagonists, Anticholinergics, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, and Others), By Application (Chemotherapy, Gastroenteritis, Post Operative Surgery, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Antiemetics Drugs Market Insights Forecasts to 2035

• The Global Antiemetics Drugs Market Size Was Estimated at USD 7.85 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.70% from 2025 to 2035
• The Worldwide Antiemetics Drugs Market Size is Expected to Reach USD 14.45 Billion by 2035
• Asia Pacific is Expected to Grow the fastest during the Forecast Period.

The Global Antiemetics Drugs Market Size was Worth around USD 7.85 Billion in 2024 and is predicted to Grow to around USD 14.45 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 5.70% from 2025 and 2035. The market for antiemetics drugs offers opportunities in the areas of focused treatments, novel formulations, and growing medical facilities. Personalized medicine, an increase in gastrointestinal illnesses, and improvements in medication delivery technologies are the main drivers of growth.

Market Overview

The global industry devoted to the manufacture, marketing, and distribution of pharmaceuticals intended to prevent or treat nausea and vomiting is known as the antiemetics drugs market. These medications are frequently used to treat motion sickness, gastroenteritis, post-operative nausea, and nausea brought on by chemotherapy. The creation, manufacturing, and distribution of pharmaceuticals intended to prevent and treat nausea and vomiting are the main activities of the antiemetics drugs market. These medications are frequently used for several illnesses, such as motion sickness, gastrointestinal issues, post-operative rehabilitation, and nausea brought on by chemotherapy.  

The purpose of antiemetic treatments or pharmaceuticals is to prevent and treat nausea and vomiting. Increased research and development efforts, as well as an increase in cancer and gastroenteritis cases, are responsible for the antiemetics drugs market's growth. The market expansion is expected to be driven by the incidence of disorders that cause nausea and vomiting. The antiemetics drugs market is expected to develop due to the increasing number of drug approvals and research initiatives. Antiemetic drug research, development, and approvals are being made by a number of industry players, which is anticipated to support antiemetics drugs market expansion.

Report Coverage

This research report categorizes the antiemetics drugs market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the antiemetics drugs market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the antiemetics drugs market. 

Driving Factors

Rising rates of cancer and gastroenteritis, as well as an increase in research and development efforts, are major factors propelling the antiemetics drugs market's expansion. The demand is expected to rise due to the increasing prevalence of illnesses that cause nausea and vomiting, such as cancer and gastroenteritis. The side effects of nausea and vomiting have been observed in several cancer therapies and treatments, including chemotherapy and gastroenteritis treatments. Antiemetic medications can help manage these side effects while undergoing therapy. The increasing incidence of gastroenteritis and cancer is therefore expected to increase demand.   

Restraining Factors

The market for antiemetic drugs is restricted by factors such as high drug prices, unfavorable side effects, regulatory obstacles, generic competition, and low awareness in developing nations, which hinders market accessibility and growth.

Market Segmentation

The antiemetics drugs market share is classified into drug type and application. 

• The serotonin-receptor antagonists segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug type, the antiemetics drugs market is divided into serotonin-receptor antagonists, anticholinergics, dopamine receptor antagonists, neurokinin receptor antagonists, and others. Among these, the serotonin-receptor antagonists segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The growing prevalence of cancer worldwide as well as the growing usage of serotonin-receptor antagonist medications to reduce nausea and vomiting related to chemotherapy, radiation therapy, and anesthesia, are the main causes of this segment's increased revenue share and growth.

• The chemotherapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the antiemetics drugs market is divided into chemotherapy, gastroenteritis, post operative surgery, and others. Among these, the chemotherapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The growing usage of antiemetics to treat chemotherapy-related nausea and vomiting, as well as an increase in new product introductions, are the reasons for the chemotherapy segment. The nausea and vomiting brought on by both acute and delayed chemotherapy are treated with this medication.

Regional Segment Analysis of the Antiemetics Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the antiemetics drugs market over the predicted timeframe.

North America is anticipated to hold the largest share of the antiemetics drugs market over the predicted timeframe. Increased approvals for antiemetic medications in the North America region are expected to fuel regional growth. In the United States, ongoing research and development initiatives have produced safer and more effective antiemetic medications. For instance, Ondansetron, a 5-HT3 antagonist that is authorized as an antiemetic in Canada, was mentioned in an article published by the Canadian Institutes of Health Research in May 2022. During chemotherapy and after surgery, this medication is used to treat nausea and vomiting.

Asia Pacific is expected to grow at a rapid CAGR in the antiemetics drugs market during the forecast period. The Asia Pacific market is anticipated to be supported by the rising prevalence of gastroenteritis and cancer in the region, as well as the expanding supply of antiemetics. The Japanese government backs medical programs that try to improve patient outcomes and cancer care. Thus, it is projected that during the forecast period, regional growth will be driven by rising cancer occurrences along with expanding chemotherapy.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the antiemetics drugs market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• GSK plc
• Cipla Limited
• Novartis AG
• Pfizer Inc.
• Viatris Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Astellas Pharma Inc.
• Baxter International Inc.
• Glenmark Pharmaceuticals Limited
• Teva Pharmaceutical Industries Limited
• Eagle Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC
• Torrent Pharmaceuticals Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In January 2023, An intravenous injection formulation called AKYNZEO I.V. was launched by Glenmark Pharmaceuticals Ltd., by Helsinn, a Swiss biopharma business, under an exclusive license arrangement. The purpose of AKYNZEO I.V. is to stop chemotherapy-induced nausea and vomiting (CINV). Fosnetupitant (235 mg) and palonosetron (0.25 mg) are combined in a fixed dose and are offered as an IV injection that is ready to dilute.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the antiemetics drugs market based on the below-mentioned segments: 

Global Antiemetics Drugs Market, By Drug Type

• Serotonin-receptor Antagonists
• Anticholinergics
• Dopamine Receptor Antagonists
• Neurokinin Receptor Antagonists
• Others

Global Antiemetics Drugs Market, By Application

• Chemotherapy
• Gastroenteritis
• Post Operative Surgery
• Others

Global Antiemetics Drugs Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa